French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost. The new operation will offer bioconjugation services for the production of ADCs, which work by attaching a drug to a homing antibody, allowing for targeted delivery. Novasep expects to bring the facility online in the second quarter of next year. More